| Late last week there was a three-day push for Dave Lashmet's Stansberry Venture Value, all about the "Venture #87" pick he was promoting and the potential of that stock for 400% gains starting on October 31, thanks to initial sales of a new blockbuster drug for a terrible disease. We didn't get a chance to cover it before the promotion ended, but I was still curious about which disease it might be, and which stock, so I dug into the tease... just click below to... |
